Herpes Zoster News and Research RSS Feed - Herpes Zoster News and Research

Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
NYU Langone-led study to examine longer-term use of suppressive antiviral medication to reduce shingles

NYU Langone-led study to examine longer-term use of suppressive antiviral medication to reduce shingles

NYU Langone Medical Center will lead a five-year, 60-center clinical trial to evaluate new treatment protocols for herpes zoster ophthalmicus (HZO), a form of shingles that can seriously and permanently affect the eye. [More]
New collaborative initiative seeks to develop interventions for optimizing adult vaccination rates

New collaborative initiative seeks to develop interventions for optimizing adult vaccination rates

A new quality improvement initiative that aims to create effective solutions in optimizing adult vaccination rates was announced today. [More]
New collaborative initiative aims to improve adult immunization rates

New collaborative initiative aims to improve adult immunization rates

A new quality improvement initiative that aims to create effective solutions in optimizing adult vaccination rates was announced today. [More]
Researchers identify shingles as persistent risk factor for stroke

Researchers identify shingles as persistent risk factor for stroke

The study by researchers from the Department of Neurology at the University of Ulsan College of Medicine in Seoul showed that herpes zoster infection not only raised the risk of ischaemic and haemorrhagic stroke but also that of a transient ischaemic attack (TIA), a warning mini-stroke often preceding a full-blown stroke. [More]
Electronic health records could help identify people who have undiagnosed type 2 diabetes

Electronic health records could help identify people who have undiagnosed type 2 diabetes

In 2012, a group of UCLA researchers set out to mine thousands of electronic health records for a more accurate and less expensive way to identify people who have undiagnosed type 2 diabetes. The researchers got much more than they bargained for. [More]
Asthma in childhood may increase risk of shingles

Asthma in childhood may increase risk of shingles

Nearly 1 million incidences of herpes zoster, which is also known as shingles, occur every year in the U.S., with an estimated one-third of all adults affected by age 80. Despite its prevalence, particularly between ages 50 and 59, it is still unclear why some individuals will develop shingles, and others will not. [More]
Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore. [More]
Shingles vaccine can help protect elderly patients with end-stage renal disease

Shingles vaccine can help protect elderly patients with end-stage renal disease

Elderly patients with end-stage renal disease (ESRD) who received the shingles vaccine were half as likely to develop shingles compared to those who were not vaccinated. The new study from Kaiser Permanente, published in Clinical Infectious Diseases, also found the best protection against shingles was achieved when patients received the vaccination shortly after beginning dialysis. [More]
Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis. [More]
Nucala (mepolizumab) approved for treatment of asthma patients

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. [More]
ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States. [More]
First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). [More]
Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]
Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157. [More]
New approach to vaccine development is 97 per cent efficacious and  could eliminate shingles

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50... [More]
New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50. [More]
Good news for patients suffering from shingles

Good news for patients suffering from shingles

The Journal of Drugs in Dermatology is delighted to present new findings from the Mayo Clinic's Department of Dermatology showing possible relief from the complications and pain secondary to Herpes Zoster, commonly known as shingles. [More]
ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100. [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles. [More]
Advertisement
Advertisement